Tactile Systems Technology, Inc. (NASDAQ:TCMD – Get Free Report) Director Daniel L. Reuvers sold 10,938 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $14.55, for a total value of $159,147.90. Following the completion of the transaction, the director now directly owns 242,942 shares in the company, valued at $3,534,806.10. This trade represents a 4.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Tactile Systems Technology Price Performance
Shares of TCMD stock opened at $14.62 on Wednesday. Tactile Systems Technology, Inc. has a 52-week low of $11.12 and a 52-week high of $21.10. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.80 and a current ratio of 4.36. The firm has a market capitalization of $344.81 million, a P/E ratio of 20.89 and a beta of 1.20. The stock has a 50 day moving average price of $17.14 and a 200 day moving average price of $15.73.
Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.09. The business had revenue of $85.59 million during the quarter, compared to analyst estimates of $85.39 million. Tactile Systems Technology had a return on equity of 9.37% and a net margin of 5.79%. As a group, sell-side analysts predict that Tactile Systems Technology, Inc. will post 0.7 earnings per share for the current year.
Institutional Investors Weigh In On Tactile Systems Technology
Wall Street Analysts Forecast Growth
TCMD has been the subject of several research analyst reports. Oppenheimer cut Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. BTIG Research cut Tactile Systems Technology from a “buy” rating to a “neutral” rating in a report on Tuesday, November 5th. StockNews.com cut Tactile Systems Technology from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 16th. Finally, B. Riley lowered Tactile Systems Technology from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $23.00 to $18.00 in a research note on Wednesday, February 19th.
View Our Latest Report on TCMD
About Tactile Systems Technology
Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.
Further Reading
- Five stocks we like better than Tactile Systems Technology
- Election Stocks: How Elections Affect the Stock Market
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Stock Market Sectors: What Are They and How Many Are There?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Short Selling – The Pros and Cons
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.